Tenax Therapeutics (TENX) Share-based Compensation (2010 - 2026)

Tenax Therapeutics (TENX) has 14 years of Share-based Compensation data on file, last reported at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 29.05% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $17.1 million (up 243.66% YoY), and the FY2025 full-year result was $19.2 million, up 25.25% from the prior year.
• Share-based Compensation slipped to $2.8 million in Q1 2026, from $4.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $26.5 million in Q2 2025 to a low of $9000.0 in Q3 2024.
• A 3-year average of $5.0 million and a median of $2.8 million in 2026 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 264900.0% in 2025 and slipped 29.05% in 2026, its largest moves.
• Tracing TENX's Share-based Compensation over 3 years: stood at $965000.0 in 2024, then surged by 396.37% to $4.8 million in 2025, then tumbled by 40.75% to $2.8 million in 2026.
• Business Quant data shows TENX's Share-based Compensation at $2.8 million in Q1 2026, $4.8 million in Q4 2025, and $5.5 million in Q3 2025.